Avid Bioservices Inc, a US-based biologics contract development and manufacturing organisation (CDMO), announced on Monday the appointment of Kerri McCullough Wood as chief commercial officer.

McCullough Wood has nearly three decades of biopharma experience across API, CDMO, and drug product services. She joins Avid following her role as chief commercial officer at TAPI, a division of Teva, where she led a global organisation spanning 15 countries, and was responsible for executing commercial strategy, accelerating growth initiatives, building strong partnerships with global pharmaceutical companies, and enhancing organisational performance across the business.

In her new role, McCullough Wood will lead Avid's global commercial organisation, including business development, marketing, and strategic partnerships. She will focus on accelerating pipeline growth, strengthening client relationships, and further aligning Avid's commercial strategy with its expanding capabilities across early-phase development through commercial manufacturing.